Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-11-14
2011-12-20
Krass, Frederick (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S046000, C424S144100
Reexamination Certificate
active
08080554
ABSTRACT:
A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune cell-mediated tumor destruction.
REFERENCES:
patent: 5391568 (1995-02-01), Chung
patent: 5543508 (1996-08-01), Haseloff et al.
patent: 5545627 (1996-08-01), Jacobson et al.
patent: 5814667 (1998-09-01), Mitchell et al.
patent: 5859019 (1999-01-01), Liang et al.
patent: 6147878 (2000-11-01), Heselton
patent: 6180133 (2001-01-01), Quan et al.
patent: 6316435 (2001-11-01), Byrd et al.
patent: 2001/0022980 (2001-09-01), Bell et al.
patent: H10-506265 (1998-06-01), None
patent: WO 96/02555 (1996-02-01), None
patent: WO 00/03741 (2000-01-01), None
patent: WO 01/39777 (2001-06-01), None
Shiozaki et al, Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP, Psychopharmacology (1999) 147:90-95.
Koshiba et al, Memory of Extracellular Adenosine A2A Purinergic Receptor-mediated Signaling in Murine T Cells,vol. 272, No. 41, Issue of Oct. 10, pp. 25881-25889, 1997.
Sullivan et al, Role of A2A Adenosine Receptors in Inflammation, Drug Development Research 45:103-112 (1998).
Gupta et al (Postgrad. Med. J. 2005; 81;236-242).
Toes et al (Journal of Experimental Medicine, 189:5 (1999) 753-756).
Qin (Immunity, vol. 12, 2000, pp. 677-686).
Hasko et al (The FASEB Jouranl, vol. 14 (2000) 2065-2074).
Shiozaki et al (Psychopharmacology (1999) 147:90-95).
NIH News Release, “Damping the Flames: Inflammation Control Mechanism Determined,” Dec. 19, 2001, National Institutes of Health, Rockville, Maryland.
Ohta and Sitkovsky, “Role of G-Protein-Coupled Adenosine Receptors in Downregulation of Inflammation and Protection from Tissue Damage,”Nature 414:916-920 (2001).
Bandyopadhyay and Poddar, “Theophylline-Induced Changes in Mammalian Adenosine Deaminase Activity and Corticosterone Status: Possible Relation to Immune Response,”Methods Find. Exp. Clin. Pharmacol. 19:181-184, 1997.
Barcz et al., “Adenosine Receptor Antagonism Causes Inhibition of Angiogenic Activity of Human Ovarian Cancer Cells,”Oncol. Rep. 7:1285-1291, 2000.
Braun et al., “Immuno Enhancing Effects of Theophylline,”Bacteriol. Proc. 71:72, 1971.
Byfield et al., “Mice, Men, Mustards, and Methylated Xanthines: The Potential Role of Caffeine and Related Drugs in the Sensitization of Human Tumours to Alkylating Agents,”British J. Cancer 43:669-683, 1981.
Devasagayam and Kesavan, “Radioprotective and Antioxidant Action of Caffeine: Mechanistic Considerations,”Indian J. Exper. Biol. 34:291-297, 1996.
Hasko et al., “Adenosine Inhibits IL-12 and TNF-α Production Via Adenosine A2aReceptor-Dependent and Independent Mechanisms,”FASEB J. 14:2065-2074, 2000.
Hess, S., “Recent Advances in Adenosine Receptor Antagonist Research,”Expert Opinion on Therapeutic Patents 11:1533-1561, 2001.
Keddie et al., “In vivo characterisation of ZM 241385, a selective adenosine A2A receptor antagonist,”Eur. J. Pharmacol. 301:107-113, 1996.
Slattery et al., “Mouse Interferons: Production by Ehrlich Ascites Tumour Cells Infected with Newcastle Disease Virus and its Enhancement by Theophylline,”J. Gen. Virol. 49:91-96, 1980.
Werner and Jolles, “Immunostimulating agents: what next? A review of their present and potential medical applications,”Eur. J. Biochem. 242:1-19, 1996.
Chen et al., “Neuroprotection by Caffeine and A2AReceptor Inactivation in a Model of Parkinson's Disease,”J. Neurosci. 21:1-6, 2001.
Chen, “The Adenosine A2AReceptor as an Attractive Target for Parkinson's Disease Treatment,”Drug News Perspect. 16:597-604, 2003.
Gale, “A2a Adenosine Receptors Limit Inflammatory Responses,” Reuters Health, Dec. 21, 2001.
Hoskin et al., “2-Chloroadenosine Inhibits the MHC-Unrestricted Cytolytic Activity of Anti-CD3-Activated Killer Cells: Evidence for the Involvement of a Non-A1/A2Cell-Surface Adenosine Receptor,”Cell. Immunol. 159:85-93, 1994.
Hoskin et al., “Adenosine Acts Through an A3Receptor to Prevent the Induction of Murine Anti-CD3-Activated Killer T Cells,”Int. J. Cancer. 99:386-395, 2002.
Kalinichenko et al., “Norepinephrine-Mediated Inhibition of Antitumor Cytotoxic T Lymphocyte Generation Involves a β-Adrenergic Receptor Mechanism and Decreased TNF-α Gene Expression,”J. Immunol. 163:2492-2499, 1999.
Kirkpatrick, “Putting the Brake on Inflammation,”Nature Rev., vol. 1, 2002.
MacKenzie et al., “Adenosine Inhibits the Adhesion of Anti-CD3-Activated Killer Lymphocytes to Adenocarcinoma Cells Through an A3Receptor,”Cancer Res. 54:3521-3526, 1994.
Nourshargh, “Adenosine Comes Home,”BPS Bulletin, pp. 5 and 10, 2001.
Ohta et al., “A2A Adenosine Receptor Protects Tumors from Antitumor T Cells,”Proc. Natl. Acad. Sci. USA 103:13132-13137, 2006.
Sikora et al., “Cutting Edge: Purinergic Signaling Regulates Radical-Mediated Bacterial Killing Mechanisms in Macrophages Through a P2X7-Independent Mechanism,”J. Immunol. 163:558-561, 1999.
Sullivan et al., “Neutrophil A2AAdenosine Receptor Inhibits Inflammation in a Rat Model of Meningitis: Synergy with the Type IV Phosphodiesterase Inhibitor, Rolipram,”J. Infect. Dis. 180:1550-1560, 1999.
Sullivan et al., “Cyclic AMP-Dependent Inhibition of Human Neutrophil Oxidative Activity by Substituted 2-Propynylcyclohexyl Adenosine A2AReceptor Agonists,”Br. J. Pharmacol. 132:1017-1026, 2001.
Sullivan et al., “A2AAdenosine Receptor Activation Improves Survival in Mouse Models of Endotoxemia and Sepsis,”J. Infect. Dis. 189:1897-1904, 2004.
Tilley et al., “Mixed Messages: Modulation of Inflammation and Immune Responses by Prostaglandins and Thromboxanes,”J. Clin. Invest. 108:15-23, 2001.
Williams et al., “Adenosine Acts Through a Novel Extracellular Receptor to Inhibit Granule Exocytosis by Natural Killer Cells,”Biochem. Biophys. Res. Commun. 231:264-269, 1997.
Yu et al., “Selective Inactivation or Reconstitution of Adenosine A2AReceptors in Bone Marrow Cells Reveals their Significant Contribution to the Development of Ischemic Brain Injury,”Nat. Med. 10:1081-1087, 2004.
Ohta Akio
Sitkovsky Michail V.
Klarquist & Sparkman, LLP
Krass Frederick
Packard Benjamin
The United States of America as represented by the Secretary of
LandOfFree
Methods for using extracellular adenosine inhibitors and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for using extracellular adenosine inhibitors and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for using extracellular adenosine inhibitors and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4297254